Press Room

Event

12th American DDF Summit - Drug Delivery and Formulation

Start
Monday, September 26, 2022 - 09:00
End
Tuesday, September 27, 2022 - 18:00
Location: San Diego, USA
Booth Number: 13
Hovione is the Official Partner of the 12th DDF USA Summit 2022

 

HOVIONE PRESENTATION

 

Pedro Valente | Hovione

 

September 27th

“Solution Spotlights – Technology & Innovation” session

with Pedro Valente

R&D Director - Oral Drug Product Development

 

 

Download a copy of the presentation

 

 

Streamlining end-to-end amorphous formulation development into a tablet suitable for Continuous Direct Compression

 

  •  Learn how bioavailability enhancement of Amorphous Solid Dispersions (ASDs) can vary from one to three orders of magnitude by optimizing both ASD and tablet formulations and processes
  • Learn how state-of-the-art tools and methodologies can shorten time to Phase I/IND by accelerating formulation and development process 
  • Learn how Dispersome(R) technology, based on natural proteins derived from milk, broaden the formulation landscape enabling high drug load and high performing formulations
  • Learn how ASD formulations manufactured by spray drying can be designed to be directly compressible by Continuous Tableting
  • Learn more how Continuous Tableting is enabling disruptive innovations in the Pharma industry with respect to quality, scalability and improving supply chain flexibility and broadening Lifecycle Management options

 

 

At Hovione we are constantly innovating to find better and more efficient ways of doing things.

 

  • If you are developing a novel drug formulation or improving your drug candidate, learn how the Dispersome® technology can increase drug solubility with clear benefits for patients

     
  • If you are looking for the most advanced and accurate screening platform able to identify the most efficient and stable Amorphous Solid Dispersion formulations by Spray Drying, learn more about ASD-HIPROS 

     

If you are interested in turning your most difficult challenge into a successful solution, schedule a meeting today to know how Hovione experts can support your project.

 

 

Find more at DDFSummit.com

 

 

Also in the Press Room

See All

The CDMO’s New Jersey manufacturing site expansion will eventually cover more than 200,000 square feet. Portugal-based contract development and manufacturing organisation (CDMO) Hovione has completed an initial $100 million investment round in its East Windsor, New Jersey site. Once completed it will increase the facility’s footprint to more than 200,000 square feet and more than double its capacity for spray drying. Hovione CEO Jean-Luc Herbeaux said: “Since launching our New Jersey operations in 2002, Hovione has been one of the longest established European CDMOs in the United States. “This investment reinforces Hovione’s leadership in spray drying – a core technology platform where we have built extensive know-how and capabilities. By continuing to advance our platforms and expand capacity in the US, we are strengthening the foundation that enables our partners to bring complex medicines to patients more efficiently.” Spray drying is an increasingly important particle engineering technology for improving drug bioavailability through the amorphous solid dispersion (ASD) that can address bioavailability or crystallisation challenges. The initial phase of Hovione’s expansion will include a 31,000-square-foot building to house two size-3 spray dryers (PSD-3) designed for ASD production. Construction at the New Jersey site is already underway and the company plans to start GMP operations in the second quarter of 2026. The initiative is part of Hovione’s long-term strategy to grow its US operations and enhance its integrated drug substance, drug product intermediate and drug product capabilities. Herbeaux said: “This investment addresses growing customer demand for US-based capacity and integrated solutions that shorten development timelines and reduce tech transfer complexity. By consolidating development, scale-up, and commercial manufacturing within a single quality and governance framework, we provide customers with seamless execution from drug substance to drug product.” The company’s New Jersey expansion fits into its wider international growth plan that also includes capacity investments in Ireland and Portugal as it seeks to create a network of autonomous sites spanning the development and commercialisation of APIs, drug product intermediates and drug products.   Read the full article at EuropeanPharmaceuticalReview.com  

Press Clipping
European Pharmaceutical Review, 4 November 2025

Hovione doubles spray drying capacity with $100m US investment round

Nov 04, 2025

US-base manufacturing and the continued rise of peptides were among the key themes for CDMOs at CPHI Frankfurt 2025. Andrew Warmington reports. Hovione announced during this show that it has completed an initial $100 million investment phase in the expansion of its manufacturing footprint in East Windsor, New Jersey. The company was one of the first European CDMOs to set up in the US back in 2002. CEO Jean-Luc Herbeaux said that when he took over the role four years ago, Hovione's footprint in the US was limited and the site was reaching capacity limitations. (...) Read the full article on SpecChemOnline.com  

Article
Speciality Chemicals, Nov./Dec. 2025

Coming to America - Drug Product Focus

Nov 01, 2025

The latest from CDMOs, CMOs, and suppliers featuring Thermo Fisher Scientific, Lonza, SK pharmteco/Lotte Biologics, Hovione, Sai Life Sciences, BioCina, Alcami, Piramal Pharma/IntoCell and Roquette. Formulation Development/Drug Product Manufacturing: Hovione Completes Initial $100-M Investment Cycle in US Operations Hovione, a CDMO of drug substances and drug products, has completed an initial $100-million investment cycle at its site in East Windsor, New Jersey, as part of a strategy to increase its US operations and enhance its integrated drug-substance, drug-product intermediate, and drug-product capabilities. Upon completion, the site will cover more than 200,000 square feet.   The initial expansion phase includes a 31,000-square-foot building that will house two size-3 spray dryers (PSD-3) designed for production of amorphous solid dispersions (ASDs). This investment more than doubles Hovione’s spray-drying capacity in the US by expanding capabilities for ASD development and commercial manufacturing. Construction is underway at the New Jersey site, with GMP operations planned to start in the second quarter of 2026.  As part of this expansion, Hovione has also acquired additional adjacent land to enable future growth at the East Windsor site. The 125,000-square-foot greenfield will support large-scale production, including continuous and batch tableting capacity, and introduce the latest pharmaceutical technologies and digital innovation with enhanced quality control and R&D capabilities.    Read the full article at DCATvci.org  

Press Clipping
DCAT Value Chain Insights, 30 October 2025

Supplier News: Thermo Fisher, Lonza, SK pharmteco, Hovione & More

Oct 30, 2025

Also in Events

See All